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Abstract
In 2003, Ruth Faden and eighteen other colleagues argued that a "problem of unequal biological
access" is likely to arise in access to therapies resulting from human embryonic stem cell research.
They showed that unless deliberate steps are taken in the United States to ensure that the human
embryonic stem cell lines available to researchers mirrors the genetic diversity of the general
population, white Americans will likely receive the benefits of these therapies to the relative
exclusion of minority ethnic groups.
Over the past five years the problem of unequal biological access has not received much attention
from politicians, bioethicists and even many researchers in the United States, in spite of the widely
held belief in the country that there is an obligation to prevent and correct ethnic disparities in
access to medical care. The purpose of this paper is to increase awareness of the problem of
unequal biological access and of the need to do more than is currently being done to ensure that
ethnic disparities in access to human embryonic stem cell-based therapies do not arise.
Specifically, this paper explains why the problem of unequal biological access will likely arise in the
United States in such a way that white Americans will disproportionately receive most of the
benefits of the therapies resulting from human embryonic stem cell research. It also argues for why
there is an obligation to prevent these ethnic disparities in access from happening and outlines four
steps that need to be taken towards meeting this obligation.
Introduction
In an article published in late 2003, Ruth Faden and eight-
een other prominent scientists and bioethicists drew
attention to "the problem of unequal biological access" in
human embryonic stem cell research [1]. Faden and her
colleagues showed that unless deliberate steps are taken in
the United States to ensure that the set of human embry-
onic stem (hES) cell lines available to researchers mirrors
the genetic diversity of the general population, there is a
good chance that white Americans will receive the thera-
peutic benefits of this research to the relative exclusion of
minority ethnic groups. These authors recognized the
injustice of this outcome and rightly stressed our obliga-
tion to avoid it.
In spite of the efforts of Faden and her colleagues (and
others [2]) to draw attention to the problem of unequal
biological access, the events of the last five years have
shown that many politicians, bioethicists, and even many
researchers in the United States continue to be unaware of
it. During this time, public policies related to hES cell
research have been debated and implemented and new
discoveries in this area of research have been heralded and
dismissed without much attention being paid to how they
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might exacerbate or mitigate this problem. The following
examples illustrate this.
The first one concerns the debate over the Stem Cell
Research Enhancement Act (H.R. 810), passed by the
United States Congress in 2005 and 2007, and vetoed by
President Bush both times. The purpose of this bill was
to loosen the restrictions imposed by the U. S. federal
policy that limits federal funding to just those hES cell
lines in existence prior to August 9, 2001. The bill would
have allowed funding for research on hES cell lines cre-
ated after this date as long as they were derived from
"discarded embryos," that is, from donated embryos left
over from fertility treatments [3]. What is salient about
this debate is that discussions of this act in Congress, in
academic journals, and in the media centered almost
exclusively on whether someone who opposes hES cell
research because embryos are destroyed could consist-
ently agree that it is morally preferable to use discarded
embryos for research rather than waste them. What was
not discussed much, if at all, is the impact that loosening
the restrictions of the federal policy would have had on
the problem of unequal biological access. Some of those
engaged in this debate did claim at the time that allow-
ing additional hES cell lines to be created using federal
funding would extend the benefits of hES cell research to
more people, but there was little discussion of whether
these benefits would be more equally distributed across
the general population.
A second example is the National Stem Cell Bank that the
National Institute of Health (NIH) authorized to be estab-
lished in 2005 at the WiCell Research Institute, a "sup-
porting organization" of the University of Wisconsin –
Madison [4]. Faden and her colleagues had argued
roughly two years earlier that a just, public hES cell bank
was the way to address the problem of unequal biological
access. Indeed, their paper was really a call to recognize an
obligation to ensure that any banks created address this
problem by mirroring the genetic diversity of the Ameri-
can population. And yet, the National Stem Cell Bank was
created without any apparent recognition of this obliga-
tion. Press releases by the NIH announcing the creation of
the National Stem Cell Bank emphasize how it will facili-
tate research by making the hES cell lines approved for
federal funding available to more researchers at signifi-
cantly less cost [5]. However, these releases make no men-
tion of the problem of unequal biological access even
though Faden and her colleagues argued that ameliorating
this problem is a strong reason to create such a bank. As
of this writing, there is also no recognition of the problem
anywhere on the website for the National Stem Cell Bank.
There are no links to any discussion of the problem and
how the bank may or may not address it. For that matter,
there are no links to any discussion of the genetic diver-
sity, or lack thereof, of the twenty-one hES cell lines avail-
able to researchers through the site. From the information
given on this website one could only have the mistaken
impression that the problem of unequal biological access
is not a problem at all.
The third example is the initiatives by various states to
publicly fund hES cell research that does not qualify for
federal funding. California, for instance, has allocated
three billion dollars over ten years to support the efforts of
in-state universities and institutions to pursue such
research. Public funds can be used in California for hES
research done with hES cell lines derived from discarded
embryos after August 9, 2001, as well as for research on
perfecting the use of somatic cell nuclear transfer (SCNT)
to create embryos from which hES cells could then be
obtained [6]. Six other states have similar initiatives,
although none of these have allocated the same level of
funding to support hES cell research in their states, and
some limit funding to just hES cell lines derived from dis-
carded embryos [7]. What is significant about these initi-
atives given the present discussion is how state officials
have justified the need for them to their constituents.
While these officials have certainly emphasized that these
initiatives are necessary for ensuring that the full thera-
peutic benefits of hES cell research are realized given the
restrictions of the federal policy, their other main point of
emphasis has often been the economic benefits and pres-
tige that are likely to result from attracting hES cell
researchers and biotechnology companies to the states
they represent [6,8,9]. What these officials have not
stressed much, if at all, however, is the potential impact of
these initiatives on the problem of unequal biological
access as it is likely to arise in their respective states. There
seems to be little awareness of this problem among these
officials, even though, as we shall see, the initiatives they
support could potentially play a significant role in amel-
iorating its effects.
The final example is the announcements last year by two
research groups of their success at "deprogramming"
human epithelial cells back to a pluripotent state simply
by introducing and expressing four genes [10,11]. These
"induced pluripotent stem cells" (iPS cells) are believed to
have the same properties as hES cells. If this is true, this
method offers the best chance so far of addressing the
problem of unequal biological access, and yet, little men-
tion of this possibility has been made in most media
reports heralding these researchers' results. Instead, the
excitement generated has largely been due to the claims of
various scientists, politicians and reporters that these
researchers have discovered a way to achieve all of the
benefits of hES cell research without the accompanying
ethical objections arising from the destruction of
embryos.Philosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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This paper is motivated by the belief that those of us living
in the United States need to begin taking the problem of
unequal biological access more seriously than we cur-
rently are. hES cell research is rapidly moving towards the
point when the first therapies using hES cells will become
available to patients. Since most will agree that we have an
obligation to ensure that access to these therapies is
equally distributed across the general population of the
United States, we need to begin taking the steps now to
make certain that this obligation is met. Thus, the aim of
this paper is to draw attention to the problem of unequal
biological access once again with the intent of increasing
the pressure on all those involved to openly acknowledge
it and to do more than is currently being done to address
it.
Specifically, I do the following in this paper. I begin by
explaining why there is concern that the problem of une-
qual biological access will arise in the United States unless
deliberate steps are taken to prevent it. Crucial here is the
fact that currently researchers almost exclusively derive
hES cells from discarded embryos. Since, as I show, it is
mostly white Americans who donate these embryos, this
makes it highly likely that whatever therapies are devel-
oped using these cell lines will benefit white Americans to
the relative exclusion of most others in the general popu-
lation. I next argue that we have an obligation to address
the problem of unequal biological access so as to prevent
this disparity in access to hES cell-based therapies from
occurring. Finally, I lay out four steps that we need to take
to solve the problem of unequal biological access. As a
part of this discussion, I consider what, besides simply
being unaware of it, is the likely reason that the problem
of unequal access has not been taken seriously so far.
Many seem to think that new methods for generating
human pluripotent cells, such as SCNT or the iPS cell tech-
nique, will become available that will either circumvent
the problem or enable researchers to mitigate its negative
effects. I show why there is good reason not to rely on
these methods to solve the problem of unequal biological
access to the therapies that may arise from hES cell
research.
The problem of unequal biological access: regenerative 
therapies
The ability of hES cells to become any kind of cell in the
human body – what scientists call their "pluripotency" –
leads many researchers to believe that they have the
potential for two kinds of therapeutic applications. One
involves using these cells as the basis of "regenerative ther-
apies," where hES cells are differentiated into specific
kinds of tissues for transplant into patients. The goal of
those pursuing this kind of application is to develop tis-
sues to treat such diseases and afflictions as Parkinson's,
Alzheimer's, diabetes, spinal cord injury, stroke, burns,
and heart disease. They also hope eventually to succeed at
growing whole organs to alleviate the chronic shortage
faced by those needing a whole organ transplant. The
other therapeutic application currently being pursued by
researchers involves differentiating hES cells into specific
tissues that can then serve as models for studying the
development, progression and possible treatments of dis-
eases that target these tissues. Besides allowing researchers
to study diseases and treatments at all stages of a disease's
development, these hES cell-based models would over-
come the most significant limitation that arises from
using animal models for medical research. Since these
models consist of human cells, there is no question of
whether findings can be extended to human beings.
The problem of unequal biological access arises in the
context of both of these therapeutic applications. Since
Faden and her colleagues have already shown in their arti-
cle how this problem arises in the case of hES cell-based
regenerative therapies, my discussion of it in the context
of these therapies in this section will mostly summarize
their work. Faden and her colleagues, however, have little
to say about the problem of unequal biological access as
it arises in the context of tissue models. So, my discussion
of the problem in this context, which I undertake in the
next section, will go beyond what they provide.
Assuming that researchers will be able to coax hES cells to
differentiate into the specific kinds of tissues needed for
transplant, the main obstacle to the success of hES cell-
based therapies is immune rejection. Unless there is a cer-
tain type of genetic compatibility between the transplant
and the patient, the transplant will be rejected and
destroyed by the patient's immune system. More specifi-
cally, immune rejection is controlled by genes that code
for a kind of protein called the "human leukocyte anti-
gens" (HLA). These HLA proteins are on the surfaces of
just about all of a person's cells, and except in abnormal
cases, they keep a person's immune system from attacking
its own tissues. Each person's immune system recognizes
its own HLA protein type and refrains from attacking any
tissues that have it. Any tissues identified as having a for-
eign HLA protein type, on the other hand, are attacked
and destroyed. Embryonic stem cells and all subsequent
cells derived from them have HLA proteins. Thus, any
transplanted tissues created from these cells will be
attacked and destroyed by the recipient's immune system
if they do not have the same HLA protein type as the recip-
ient. There are only two ways to keep this type of rejection
from happening. One is to match transplanted tissues to
recipients based on HLA protein type. In cases where such
a match is possible, rejection may be avoided altogether
or the threat of it may be significantly reduced. The other
is to use immunosuppressive drugs to keep the immune
system from attacking the transplant. Using the drugs thatPhilosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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are currently available, however, is financially burden-
some to patients and often causes additional serious
health complications. For these reasons, in most cases,
obtaining an HLA match is seen as the more desirable of
these two options.
The problem with matching HLA protein types, however,
is that it proves to be rather difficult to do. First, three sets
of genes play important roles in regulating immune rejec-
tion- HLA-A, HLA-B and HLA-DR. Second, these genes are
highly polymorphic, which means that there is significant
variability in these genes among the general population. A
variant of a gene is referred to as an "allele." As humans
are diploid, having two alleles of every gene, obtaining a
complete match in HLA protein types between a donor
and a recipient requires matching the two alleles of each
of these three HLA genes.
To illustrate just how difficult it is to obtain an HLA match
between recipient and donor, Faden and her colleagues
draw attention to the registry maintained by the U. S.
Bone Marrow Donor program. This registry is a list of over
four million donors who have had their HLA-A and HLA-
B alleles typed. Faden and her colleagues note that "Due
to the high degree of polymorphism in the relevant alle-
les, even with this enormous pool of donors only 50 to 60
percent of patients who need transplants can find a
match" [[1], p. 17].
Further complicating attempts to obtain an HLA match is
the fact that HLA expression "tracks with geographical
ancestry" [[1], p. 15]. HLA alleles occur with different fre-
quencies within each ancestral group. Alleles common to
one group may be much less common in another. As evi-
dence of this, Faden and her colleagues give the example
that "the ten most common HLA-A alleles in white Amer-
icans are not the ten most common in African Americans,
and vice versa" [[1], p. 17]. This fact about HLA distribu-
tions complicates matters because it means that success in
finding an HLA match will depend on which ancestral
groups are represented in the donor pool. Members of
groups that are underrepresented in this pool may have
significantly greater difficulty finding a match, while indi-
viduals from groups that are better represented will find it
much easier.
It is this last point that gives rise to the concern that the
problem of unequal biological access will arise in the case
of hES cell-based regenerative therapies. There is good rea-
son to think based on what we know about the pool of
embryos from which existing hES cell lines were derived
(i.e., those currently available for use in federally funded
research and those that have more recently been created
for state or privately funded research) that the genotypes
of ethnic minorities are underrepresented and those of
white Americans are overrepresented in these lines. The
vast majority of these lines were derived from discarded
embryos left over from fertility treatments utilizing in vitro
fertilization. Studies show that there is significant ethnic
disparity in the use of reproductive technologies within
the general population of the United States [12-14]. Afri-
can Americans and Hispanics, for instance, underutilize
these services, while white Americans utilize them to a
much greater degree. This disparity strongly suggests that
any existing hES cell lines derived from discarded
embryos came from a pool of embryos that was likely
genetically biased in favour of white Americans and that
this will continue to be true in the case of any future hES
cell lines also derived from this pool. Given what has been
said above about the importance of HLA matching, this all
boils down to an increased likelihood that white Ameri-
cans will have significantly greater access to hES cell-based
regenerative therapies than everyone else as long as
researchers continue to use discarded embryos as the
source of their hES cell lines.
Two additional points need to be made here. First, it is
true that in the case of organ transplantation the impor-
tance of HLA matching has been shown to vary depending
on what type of organ is transplanted [15]. For instance,
kidneys are sensitive to rejection and a close HLA match is
essential to a good clinical outcome. Livers, on the other
hand, are less sensitive and obtaining a close HLA match
is not regarded as a top priority. Hearts and lungs fall in
between. Thus, the extent to which there will be ethnic
disparities in access to hES cell-based regenerative thera-
pies if the problem of unequal biological access is not
addressed will certainly depend on the type of regenera-
tive therapy that is in question.
Second, immunosuppressive drug therapies can also be
used to increase access to hES cell-based therapies in cases
where a good HLA match is not possible. However, given
that the use of these drugs imposes significant financial
burdens and health risks on patients, increasing ethnic
minorities' access to regenerative therapies by means of
these drugs will not be sufficient for addressing the prob-
lem of unequal biological access. Since ethnic minorities
would be forced to endure these burdens and risks dispro-
portionately to white Americans, the problem still
remains. To address the problem of unequal biological
access adequately using immunosuppression, what is
needed is a therapy that makes the risks and expense of
regenerative therapies in these cases comparable to those
that involve good HLA matching. Some recent reports sug-
gest that one therapy, "mixed chimerism," has promise
along these lines [16,17]. It involves temporarily sup-
pressing the immune system of the recipient and trans-
planting bone marrow from the organ donor into the
recipient prior to the actual organ transplant. When suc-Philosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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cessful, this therapy creates a chimeric immune system in
the recipient, consisting of the recipient's and the donor's
immune cells, that does not reject the transplanted tissue.
This therapy still has a way to go before its long-term effec-
tiveness and safety is established. However, if these are
ever established, this therapy would certainly prove signif-
icant for addressing the problem of unequal biological
access. Until then, the lack of genetic diversity in the hES
cell lines available to researchers must remain a concern.
The problem of unequal biological access: tissue models
While the use of hES cells for regenerative therapies often
receives the most attention in discussions of the potential
benefits of hES cell research, many researchers see the
more immediate benefits, and perhaps even the more sig-
nificant ones, as coming from the use of these cells to cre-
ate "tissue models" for studying the development and
possible treatment of various diseases. For instance, one
strategy currently being pursued is to use preimplantation
genetic diagnosis to genetically screen embryos for partic-
ular genetic diseases, derive hES cells from those predis-
posed for these diseases and then generate diseased tissues
using those cells. This then would allow researchers to
study the development of the disease from its earliest
stages and to test treatments at any point. It is striking
what this could someday mean for a disease such as cystic
fibrosis, an inherited disease of the mucus glands which
causes progressive damage to the respiratory system and
chronic digestive problems among others. While research-
ers know that cystic fibrosis is caused by a mutation in the
CFTR gene, they suspect that other factors, both environ-
mental and genetic, influence the disease's progression
and are the reason why some with the disease are more
severely afflicted than others. Having a cystic fibrosis dis-
ease model would give researchers a powerful tool for iso-
lating and identifying these factors.
Another strategy is to use hES cells to develop tissue
models that are not diseased for use in testing the effec-
tiveness and toxicity of drugs. For example, this strategy
is currently being pursued at the University of Georgia
where researchers are looking for ways to combat spinal
muscular atrophy or SMA, the number one genetic killer
of children under two years old. SMA is caused by a
defect in one of the two survival motor neuron (SMN)
genes that people have, a set of genes responsible for
producing a protein necessary for the proper develop-
ment and functioning of motor neurons. In children
with SMA, the second SMN gene does produce this pro-
tein, but not in amounts sufficient to keep the child's
motor neurons from degenerating. Researchers at the
University of Georgia hope to produce systems of motor
neurons from hES cells to test the effectiveness and tox-
icity of drugs that offer the promise of increasing SMN
protein levels [18].
Unlike researchers working towards hES cell-based regen-
erative therapies, researchers looking to develop hES cell-
based tissue models do not encounter the obstacle of
immune rejection, since the tissues they generate will not
be used for transplants. However, having genetically
diverse hES cell lines to work with is still essential for
those developing these models.
It is well documented that genetic variability has a role in
determining whether a person develops a specific disease.
The gene or genes responsible for the disease may be pol-
ymorphic and the development of the disease and its
severity may depend on which alleles of the gene the per-
son carries. And, often, diseases are "polygenic," meaning
that the presence of specific alleles of other genes is neces-
sary for a disease to develop. Many high profile diseases,
such as heart disease, cancer and diabetes, seem to fall
into this category. It is also well known that the effective-
ness and toxicity of drugs often depend on which alleles
of specific genes a person has, most often because these
variations affect how drugs are metabolized. For instance,
a group of enzymes found in the liver and gut called the
"cytochrome P450 system" plays an important role in
metabolizing many drugs. Each of these enzymes is the
expression of an individual gene, and so far, over fifty
P450 genes have been identified. Moreover, there are
many alleles of each these fifty genes, and a drug's effec-
tiveness and toxicity can vary greatly depending on which
allele an individual has [19]. Thus, without genetically
diverse hES cell lines there is the real risk that the resulting
lack of genetic diversity in the tissue models created from
these lines will significantly undermine the ability of
researchers to understand adequately the development of
diseases and to assess properly the effectiveness and risks
of potential treatments of them, as well as accurately
assess the potential effectiveness and toxicity of drugs as
they are metabolized in the body.
The problem of unequal biological access is specifically a
concern in this case because the genetic variations that
influence disease development and drug effectiveness can
occur with different frequencies among ancestral groups.
Cystic fibrosis is an example of a disease of which this is
true. It is much more common among white Americans
where approximately 1 in 3,200 white newborns are diag-
nosed with the disease, as compared to African Americans
and Asian Americans where roughly 1 in 15,000 and 1 in
30,000 respectively are diagnosed as having it [20].
Another example is prostate cancer where the incident rate
in African Americans (248.5 per 100,000 men) is much
greater than in white Americans (156.7 per 100,000 men)
[21]. While this difference can be partly attributable to
such factors as access to healthcare, diet and other lifestyle
characteristics, there is growing agreement that differences
in allele frequencies between ancestral groups is an under-Philosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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lying cause [22]. The genes underlying the cytochrome
P450 system, on the other hand, serve as a good example
of genes influencing drug effectiveness whose variants
often occur with different frequencies among ancestral
populations. For instance, one of these genes, CYP2D6,
has a role in converting codeine into its active form, mor-
phine. Those who have two nonfunctional alleles of
CYP2D6 are unable to make this conversion, and thus do
not experience the drug's analgesic effect. The frequencies
of these nonfunctional alleles vary significantly, ranging
from 6 percent in Asian populations to 7 percent in Afri-
can populations and 26 percent in European populations
[20]. Although these are only three of the many examples
that could be mentioned, they do illustrate what is at risk
if one ancestral group is overrepresented in the hES cell
lines used to develop tissue models.
As these examples show, genetic variants responsible for
diseases occur in all ancestral groups. Thus, they can show
up in hES cells lines derived from discarded embryos
(such as those found to be genetically defective following
PGD testing) even if one ancestral group is overrepre-
sented in them. However, the significant differences in the
frequencies of these variants between ancestral groups will
often make their appearance highly unlikely. Hence, if
one group is overrepresented in the hES cell lines availa-
ble to researchers, there is the risk of developing a biased
understanding of disease susceptibility and drug efficacy
that favors the overrepresented group and increases the
risks for those in underrepresented groups. If this overrep-
resented group does turn out to be white Americans, as
there is reason to suspect it will, then white Americans will
receive a disproportionate share of the benefits of hES cell-
based tissue models, while minority ethnic groups will be
forced to endure a disproportionate share of the risks.
Why we have an obligation to address the problem of 
unequal biological access
Recognizing that hES cell research as it is currently being
pursued – that is with discarded embryos as the primary
source of hES cell lines – will likely lead to disparities in
access benefiting white Americans to the relative exclusion
of other ethnic groups in the general population will be
enough to convince some that we have an obligation to
address the problem of unequal biological access. Others,
however, will require more to be convinced. Thus, it is
worth giving a general sense of how this problem fits into
the broader context of health and healthcare disparities in
the United States and how it is a further extension of those
disparities.
That there are disparities in healthcare and health in the
United States is well documented. For instance, health
insurance is the gateway to the healthcare system, and yet
the U.S. Census Bureau reported in 2005 that as many as
46.6 million people in the United States lack it [23].
Moreover, ethnic minorities are much more likely to be
without health insurance than white Americans. In 2005,
11.3 percent of non-Hispanic whites lacked health insur-
ance, while 19.6 percent of African Americans and 32.7
percent of Hispanics did not have it [24]. The impact of
not having health insurance on people's health and finan-
cial viability cannot be overemphasized. Those without it
are less likely to receive preventative care and thus to be in
advanced stages of a disease once they are examined by a
physician. They also tend to be sicker upon being admit-
ted to a hospital and thus more likely to die after being
admitted. In addition, even though those without health
insurance tend to be poorer, they often have greater out of
pocket expenses and have higher rates of bankruptcy due
primarily to their medical expenses [25].
But studies also show that even when ethnic minorities
have health insurance they often receive less access to
healthcare than do white Americans. They are, for
instance, less likely to be screened for cancers, diabetes
and cardiac risk factors. They are also less likely to receive
prenatal and maternal care resulting in greater postnatal
complications for newborns and mothers and higher
infant mortality rates. And, much too often, the treat-
ments for many diseases have significantly lower success
rates for ethnic minorities than for white Americans [25].
This last point draws attention to the disparities experi-
enced by ethnic minorities in medical research. The his-
tory of this research is littered with examples where the
interests of these groups have been intentionally violated
in favor of the "interests of society," which most often
meant the interests of white Americans. The classic case, of
course, is the Tuskegee Syphilis Experiment where begin-
ning in 1932 and continuing until 1972 African American
men were intentionally denied effective treatments for
syphilis so that the effects of the disease on them could be
compared to its effects on white Americans (even though
no similar experiment was ever started on white subjects).
Other more recent cases may not involve such blatant,
intentional mistreatment, but the fact remains that they
are examples where the interests of minority ethnic groups
have not been addressed. For example, one explanation
for why some treatments are less effective for ethnic
minorities is that they are less likely to be included as sub-
jects in clinical trials. This may be partly due, as is often
claimed, to their unwillingness to volunteer for clinical
trials because of their distrust of the medical community;
however, recent studies suggest that this lack of participa-
tion is more often due to researchers failing to reach out
to members of these groups because of pre-existing beliefs
about the difficulties in recruiting them, the higher costs
in doing so and the increased likelihood of their dropping
out of trials [26].Philosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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Although much more can be said here, this gives a sense
of the context in which the problem of unequal biological
access needs to be understood. Currently, there is every
expectation that hES cell research will radically change
how some of humanity's most devastating diseases and
afflictions are treated. The success of hES cell-based thera-
pies will mean significant improvements in the overall
health and life expectancies of those who have these dis-
eases and afflictions. However, what the problem of une-
qual biological access brings to our attention is that some
minority ethnic groups, those very same groups who have
traditionally been subjected to health and healthcare dis-
parities in this country, are likely to receive significantly
less access to these therapies because the hES cell lines
available to researchers lack the genetic diversity to ensure
that this access is more equally distributed across the gen-
eral population.
But there is more. This lack of genetic diversity in these
hES cell lines is itself a direct result of ethnic disparities in
access to healthcare. I have already mentioned the extent
to which ethnic minorities underutilize the reproductive
technologies that currently supply researchers with
embryos. The reasons most often given for this underuti-
lization all point to the effects of past and current discrim-
ination experienced by these groups. Ethnic minorities
often lack the financial resources to pay for these repro-
ductive technologies, and when they do have these
resources it is common for them to face barriers impeding
their access to these technologies. Too often, ethnic
minorities are not informed of the availability of these
technologies, do not receive the necessary referrals from
their primary physicians, and are even denied access
because of ethnic discrimination [12].
Most of us agree that as members of a society that has a
history of ethnic discrimination, we have an obligation to
do whatever we can to alleviate the negative outcomes of
existing disparities and to prevent future ones from occur-
ring. One of these negative outcomes is the problem of
unequal biological access. Thus, we have an obligation to
take whatever steps we can to address this problem so as
to prevent any future disparities that are likely to result
from it. My aim in the rest of this paper is to sketch in gen-
eral terms what these steps are.
Step one: we must openly acknowledge the problem of 
unequal biological access
At the beginning of this article I mentioned four examples
to illustrate how little public attention is being paid to the
problem of unequal biological access. This lack of atten-
tion may really be because people are unaware of the
problem in spite of the attempts by Faden and her col-
leagues (and others) to draw attention to it. If so, it is
obviously my hope that this paper will increase awareness
of the problem and motivate more people to do more
about it. However, I think there are two other reasons why
the problem of unequal biological access has received
insufficient attention up to this point. I discuss these in
the next two sections.
The debate over hES cell research is highly politicized. As
a result, each side can have the tendency to emphasize
whatever it deems to be to its advantage, while ignoring
whatever is deemed otherwise. I suggest that one possible
reason why the problem of unequal biological access has
not received the attention it deserves is that often neither
side in this debate sees much to gain by drawing attention
to the problem, and perhaps even much to lose if it does
so.
This can be shown by focusing on what is at stake for each
side in the debate over the current federal policy regulat-
ing funding for hES cell research. To qualify for funding
an hES cell line must have been created from a donated,
discarded embryo prior to President Bush's announce-
ment of this policy on August 9, 2001. Proponents of this
policy regard it as a compromise between those who want
hES cell research to proceed and those who demand that
it be stopped because of its destruction of embryos.
Acknowledging the problem of unequal biological access
would, however, put these proponents of the policy in a
difficult place. Although President Bush stated in his
announcement that "more than 60 genetically diverse
stem cell lines already exist" [27] that would qualify for
funding and would eventually become available to
researchers, acknowledging the problem of unequal bio-
logical access would require admitting that the lines avail-
able to researchers are almost certainly not as genetically
diverse as the President suggested. This is a possibility
made even more likely by the fact that currently only
twenty-one qualifying lines are actually available. But, of
course, acknowledging the problem of unequal biological
access involves more than just recognizing this lack of
genetic diversity. It also means admitting that because of
this lack of diversity the federal policy, albeit unintention-
ally, increases the likelihood that disparities in access to
the benefits of hES cell-based therapies favoring white
Americans will occur. Again, this is not a place where pro-
ponents want to find themselves. They do not want to
appear to be supporting a policy that at best blocks
attempts to avoid these disparities, and at worst, exacer-
bates them.
It is more difficult to see why those who oppose the fed-
eral policy because it is too restrictive would be reluctant
to acknowledge the problem of unequal biological access.
One would think that doing so would pressure propo-
nents of the policy to support attempts to loosen its
restrictions. The situation becomes clearer, however, oncePhilosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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it is recognized that replacing the federal policy with the
one that most of these opponents endorse is unlikely to
make much progress towards addressing the problem of
unequal biological access. What these opponents often
seek is a policy along the lines of the Stem Cell Research
Enhancement Act that allows federal funding to support
research on new hES cell lines, but only if they are derived
from donated, discarded embryos. However, even though
such a policy change would mean the creation of new hES
cell lines, and perhaps even a significant number of them,
what can be concluded about the likely genetic diversity of
these discarded embryos based on what we know of who
has access to reproductive technologies gives little reason
to expect that these extra lines will make access to the ben-
efits of hES cell research much more equal. Thus, for these
opponents of the federal policy, focusing attention on the
problem of unequal biological access comes with the risk
of exposing a serious shortcoming of their own policy.
I do not see how refusing to acknowledge the problem of
unequal biological access for the reasons above can be
defended. Our obligation to address existing healthcare
disparities and to prevent future ones from occurring
amounts to an obligation to formulate public policies that
ensure that all in the general population have an equal
opportunity to access the benefits of publicly funded
medical research. It also certainly means that we have an
obligation to correct any existing policies that are likely to
lead to disparities in this access. We are not released from
these obligations just because the public policies in ques-
tion pertain to hES cell research.
The second possible reason for why the problem of une-
qual biological access has not received much attention is
less political and perhaps even more understandable.
Many who are aware of the problem may believe that
there is no need to draw attention to it because by the time
hES cell-based regenerative therapies and tissue models
are clinically viable, researchers will no longer be relying
on hES cell lines derived from discarded embryos to
develop them. Instead, the development of new tech-
niques such as SCNT, or the one used to obtain human
iPS cells, will enable researchers to produce pluripotent
stem cells that are genetically specific to individual
patients. This would eliminate the problem of unequal
biological access, since regenerative therapies and even tis-
sue models could be tailored to each patient who needs
them.
There are two points to be made here. First, researchers are
already moving forward with developing tissue models
using hES cell lines that have been derived from discarded
embryos. The work being done at the University Georgia
to develop motor neuron models to test drug treatments
for SMA is just one example. There are many other
research laboratories across the country pursuing similar
projects. At this time, there is every reason to expect that
some of the treatments being tested using these models
will become available to patients in the near future. Also,
two companies – Geron Corporation and Advanced Cell
Technology – have recently sought Food and Drug
Administration approval to begin Phase I trials testing
regenerative therapies that were developed using hES cells
from discarded embryos [28]. The point is that hES cell
research is already on the brink of moving into a therapeu-
tic stage. As I see it, we can ill afford not to acknowledge
the problem of unequal biological access or to wait to
address it until either SCNT or the iPS cell technique (or
some other one) is available, if either one ever is. For one
thing has become clear, once ethnic disparities in access to
healthcare exist, they are extremely difficult to address.
Second, even if SCNT or the iPS cell technique is success-
fully developed, neither is likely to fulfill all that it prom-
ises. Both will be able to provide researchers with patient-
specific stem cells, but it is unlikely that researchers will be
able to use either of these techniques to produce stem cells
for patients on demand. Thus, neither of these methods
will likely enable researchers to avoid the problem of une-
qual biological access by ensuring that all in the general
population who might benefit from hES cell-based thera-
pies will have access to them. Neither method is likely to
make "full access" to the benefits of hES cell research a
reality, at least not in the near future. Recognizing this and
openly acknowledging it is the second step we need to
take to address the problem of unequal access.
Step two: we must acknowledge that full access for 
everyone is not possible at this time
Being able to provide all patients with hES cell-based ther-
apies specific to their own genotypes would, of course, be
the best possible solution to the problem of unequal bio-
logical access. At least in principle no one in the general
population would be denied access to these therapies for
biological reasons alone. There would be no need to
worry about HLA matches in the case of regenerative ther-
apies and tissue models could be developed for each
patient so that drug treatments could be tested for efficacy
and safety. This degree of access is most certainly not
achievable as long as researchers rely on discarded
embryos as the source of hES cell lines, but it does seem
achievable, at least at first glance, if either SCNT or the iPS
cell technique (or both) is successfully developed. But is it
reasonable to expect either of these techniques to make
possible this degree of access?
SCNT is a technique where a nucleus from an individual's
cell is inserted into an oocyte that has had its nucleus
removed, and the re-nucleated oocyte is then stimulated
into developing. Once the resulting embryo develops intoPhilosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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a blastocyst, hES cells can then be harvested from it using
the method for deriving these cells from discarded
embryos. Since the nucleus used can be taken from any
patient's somatic cell, this technique offers a way to derive
hES cells that are genetically specific to patients.
In the United States, researchers at a number of institutions
are currently working towards developing SCNT into a reli-
able method for obtaining hES cell lines. Harvard Univer-
sity, The University of San Francisco, Stanford University,
and Memorial Sloan-Kettering Cancer Center, among oth-
ers, all have active research programs in this area supported
by state and private funding. Researchers in other countries,
such as Japan, South Korea, Great Britain and Australia, are
also working towards developing this technique. While
these researchers have yet to succeed at obtaining hES cells
using SCNT, most continue to believe that it is only a mat-
ter of time before it will be done.
But even if SCNT is developed into a reliable method for
generating patient-specific hES cells, there are good rea-
sons to think that researchers will not be able to use it to
provide hES cells on demand for every patient. First, there
is the lag time that will exist between when patients are
diagnosed as requiring an hES cell-based therapy and
when the hES cell lines genetically specific to them will
become available. It is doubtful that most patients will be
able to wait this long for their treatments to begin. Sec-
ond, there is the almost certain high cost of using SCNT to
develop patient-specific hES cells lines. We can hardly
expect sufficient financial resources to be allocated to
cover the expense of using SCNT for all patients needing
hES cell-based therapies. We might also rightly question
whether this is the best use of the limited financial
resources available for ensuring equitable access to health-
care. Further complicating these matters is that research
involving hES cells obtained using SCNT would not qual-
ify for funding under the current federal policy because of
the harm it does to embryos. Finally, third, there are
numerous ethical and practical barriers to using SCNT on
such a wide scale. For instance, SCNT would create
embryos with the specific purpose of harvesting hES cells
from them. Many people believe that there is a clear moral
difference between using discarded embryos for hES cell
research and intentionally creating embryos specifically
for this purpose. In fact, many would withdraw their sup-
port of this research in this latter case. There are also the
important questions that arise due to the reliance of this
method on donated ova. Will women be willing to donate
the number of ova that the use of this technique on such
a wide scale would require? If not, should they be paid for
donating them? How likely is it that women will be
coerced into donating their ova? Will the general public
tolerate and support the use of alternative sources of ova,
for instance, those obtained from cows or rabbits [29,30]?
For all these reasons, we should be hesitant to rely on
SCNT as the method for achieving full access.
The iPS cell technique, on the other hand, is a more prom-
ising option. Because iPS cells are derived directly from
human epithelial cells, they are a source of patient-specific
pluripotent stem cells that does not require destroying a
single embryo or using a single ovum. In this way, they
bypass all of the ethical objections that can be raised
against SCNT. Research both to produce these iPS cells
and to develop therapies from them would also qualify
for federal funding, and given the claims by researchers
that the iPS cell technique is relatively easy to use, much
easier than SCNT, it is likely that significantly less finan-
cial resources will be needed to produce patient-specific
cells on demand.
However, in spite of these advantages, it would be a mis-
take to assume at this point that the use of the iPS cell
technique will make full access possible, at least in the
near future. This technique for obtaining these stem cells
is in the earliest stages of development and is still a long
way from being used to derive iPS cells for therapeutic
applications. There is still the chance that human iPS cells
will turn out not to be pluripotent or that the technique
for producing them cannot be perfected to the point
where it can be safely and reliably used. While the very
recent report [31] by one research group of their success at
using the iPS cell technique to turn skin cells from an 82
year-old ALS patient into pluripotent stem cells that then
differentiated into motor neurons with her genetic
makeup does reinforce its viability for generating patient-
specific pluripotent stem cell lines that could then be used
for disease models, most researchers continue to believe
that tissues generated from iPS cells are unsuitable for
transplantation because one of the genes employed to
induce dedifferentiation and the retroviruses used to
insert the genes into somatic cells have oncogenic proper-
ties [31,32]. Researchers continue to stress that the use of
iPS cells for regenerative therapies will need to be delayed
until alternative methods for dedifferentiating cells
become available [31,32]. But even if this technical obsta-
cle is overcome, there is also the issue that until the tech-
nique is perfected to the point where it is actually easy to
use, and its initial costs are significantly reduced, it
remains unlikely that the iPS cell technique will be made
available to all patients who might benefit from it. In fact,
one has to be concerned that there will be disparities in
access to iPS cell based therapeutic applications as a result
of access being limited, at least initially, to just those
patients who are able to pay for it themselves. In addition,
there is the worry about lag time between diagnosis and
availability of treatment. As with SCNT, it will likely
require some months to obtain iPS cells and to develop
the appropriate tissues from them.Philosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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However, it would also be a mistake to conclude from this
that the successful development of iPS cells would not be
an important advance towards solving the problem of
unequal biological access. Once it is recognized that this
problem is unlikely to be solved in the near future by pur-
suing a strategy of providing full access, the goal has to
become one of ensuring that whatever access is possible to
achieve is more equally distributed across the general
population. This means acknowledging that Faden and
her colleagues were right in arguing that what is required
is a strategy that deliberately aims at developing a bank of
stem cells lines available to all researchers that more accu-
rately mirrors the genetic diversity of the general popula-
tion. Such a bank would not only work to address the
problem of unequal biological access, but would also help
with the lag time issue and ensure that all researchers and
clinicians have an adequate supply of pluripotent stem
cell lines available to them. For reasons already discussed,
such a bank is unlikely to be established if researchers
continue to rely on donated embryos to provide hES lines
with the required genetic diversity. Instead, they will need
a method that allows them to create pluripotent stem cell
lines with targeted genotypes. If iPS cells can be reliably
produced, they will offer the most practical and least con-
troversial way yet for generating these lines and for popu-
lating a genetically diverse and public stem cell bank. It is
here that the real value of iPS cells potentially lies, and it
will be significant even if the use of these cells is limited
to disease models.
Step three: we must publicly decide what counts as equal 
access
But even if we agree that addressing the problem of une-
qual biological access requires a public policy of deliber-
ately establishing a public and genetically diverse bank of
hES cell lines, or pluripotent cell lines generated using
alternative methods, the question remains as to which
genotypes to target for inclusion in this bank. We do have
choices here. We can, for instance, aim to maximize cov-
erage among all those in the general population. We can
also place an emphasis on treating all in the general pop-
ulation "equally" by adopting a lottery system where all
have a chance to have their genotypes included. Still
another option is to work towards ensuring that all ethnic
groups in the general population are in some way equally
represented in the bank so that no group has a dispropor-
tionate advantage. What I have said in this essay up to this
point makes it obvious that a method along the lines of
this third option would be the one I support, and in this I
am more or less in agreement with Faden and most of her
colleagues. In their paper, these authors considered all
three of these options and rejected the first two primarily
because pursuing them would increase the risk that ethnic
minorities would experience disparities in access to the
benefits of hES cell-based therapies. They chose the third
option of distributing access equally among all ethnic
groups because it mitigates this risk, while even doing
some work towards correcting already existing disparities
in health and healthcare. Of course, this option faces its
own set of questions that will need to be answered, not
the least of which will be how to determine which geno-
types within ethnic groups should be included in the
bank, which is not to say that Faden and her colleagues
have nothing important to say in response to such ques-
tions.
However, my aim here is not to defend a particular
method for selecting the hES cell lines to be included in
an public stem cell bank. Such a defense would be beyond
what I can accomplish here. Instead, I want to emphasize
how important it is that the right process be used to
choose this method.
We need to keep in mind that regardless of which method
is ultimately used to select the hES cell lines for inclusion
in a stem cell bank, some number of people who might
potentially benefit from hES cell-based therapies will be
denied access to them simply because their genotypes are
not represented in the lines selected. This fact makes it
important that our choice of a method be the product of
public deliberation of the various alternatives. Such delib-
eration serves a number of critical purposes in this case.
For one, it allows for the critical assessment and correction
of proposals, which not only increases the probability of
success, but also makes the justice of the strategy chosen
more likely, since hidden biases will be uncovered and
undesirable consequences identified. It also allows all
those who are affected by the decision to offer input into
the decision making process, which is something justice
in this case also seems to require. Given what is at stake,
all those affected should have an opportunity to shape the
decision so that their interests are addressed, and if the
decision goes against their interests, to understand the
process that led to that decision. This last point must not
underappreciated. A public and genetically diverse hES
cell bank will be much easier to establish if there is wide
public support for it including from those whose geno-
types will not be represented in it. As such, people need to
be convinced of the need for such a bank, its potential for
success, and its fairness.
The case for the importance of such a process becomes
even stronger once we recognize that much of what is
wrong with the National Stem Cell Bank could have been
avoided if a process like this one had been followed. The
purpose of this bank is to facilitate research on the twenty-
one hES cell lines that qualify for federal funding. Cer-
tainly one concern that many researchers have raised
about the National Stem Cell Bank is that this number of
lines are just too few to meet their needs. Many have alsoPhilosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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pointed out that some of these lines have changed genet-
ically or do not differentiate equally well into all tissue
kinds, and thus are limited in their suitability both for
regenerative therapies and tissue models [33]. Addition-
ally, it is well known that all of these lines were derived
using a method requiring mouse feeder cells, and thus any
regenerative therapies utilizing tissues created from them
carry the risk of transferring mouse viruses to humans
[34]. And, of course, we must question the extent to which
minority ethnic groups are represented in these lines.
After all, each of these lines was derived from a discarded
embryo, and we have already seen why this should lead us
to suspect that white Americans are overrepresented in
these lines.
The point is that these problems with the National Stem
Cell Bank are largely due to the process that led to its cre-
ation. The President announced a policy that was not sub-
jected to rigorous public debate prior to its being
announced. As a result, serious shortcomings in the policy
were not identified and corrected, which in turn has led to
a national stem cell bank that is at best ineffective and at
worse unjust. And the failure of the President to give those
who are most likely affected by this policy a chance to
shape it through their input has led many to resent it
deeply. Whether rightly or wrongly, they see it as some-
thing forced upon them by a President who is either acting
on his own religious beliefs or out of a desire to appease
his own political constituencies.
So if I am right about the process we need to pursue for
selecting a method for choosing hES cell lines for inclu-
sion in a public and genetically diverse stem cell bank, the
third step we need to take to address the problem of une-
qual biological access is clear. We need to begin the proc-
ess of publicly deliberating about the various methods
that seem to be plausible. This will require the contribu-
tion of those with expertise in ethics and law to clarify
what justice and fairness mean in this case. It will also
require the efforts of those with expertise in the biology of
stem cells, in tissue transplantation, in disease genetics,
among others, to provide the information necessary for
informed positions and choices. It also will require politi-
cians to recognize the importance of this debate, to allo-
cate the funding necessary for its taking place, and to
refrain from co-opting it for their own political agendas.
Finally, it will necessitate efforts on everyone's part to
ensure that the general public has opportunities to partic-
ipate in this debate and to be kept informed of its progress
and conclusions.
I do not want to suggest that any of this will be easy to
accomplish. Obviously, it is extremely difficult to initiate
and to sustain the kind of deliberative process I am
describing here. It is also unlikely that we will ever reach a
consensus on the method to use for selecting the hES cells
to populate the bank. Almost certainly, a public entity,
such as the NIH, will need to make the decision as to
which method to pursue. But, I do think it is right that
how this decision is reached will be crucial to garnering
wide support for creating a public stem cell bank that is
perceived by most in the general population as being just,
and thus, that it is worth our expending the effort to do all
we can to make sure that this decision is reached in the
right way. We do have mechanisms in place already to
reach decisions like this one. The President's Council on
Bioethics, for instance, is already charged with exploring
the ethical and policy questions related to bioethical
developments, which includes providing a forum for
national discussions of these developments. While it is
true that such councils can be unduly influenced and
manipulated by political pressure, as some have claimed
the current President's Council has been, a council that
successfully resists this pressure would prove invaluable to
ensuring that the process of selecting a method for popu-
lating an hES cell bank is just to all.
Step four: we need to establish a public and genetically 
diverse stem cell bank
There is reason to be concerned that this last step will not
be completed even if the other three are. As we have seen,
it would be unreasonable to expect that a genetically
diverse stem cell bank can be established using hES cell
lines obtained from discarded embryos. The hope, of
course, is that a morally uncontroversial technique, such
as the one used to obtain iPS cells, will emerge and enable
researchers to create lines with targeted genotypes so as to
populate the bank. And, as has already been noted, recent,
but still isolated reports, suggest that the iPS technique
may be viable for creating a bank for tissue models,
although their suitability for generating safe regenerative
therapies remains in doubt. But, there is still the chance
that no alternative technique for producing pluripotent
stem cells will prove to be reliable or will be adequately
developed in the near future. If this is how things turn out,
researchers working towards developing the bank will
need to solicit gametes from donors who have targeted
genotypes, intentionally create embryos from these gam-
etes, and harvest stem cells from them. This could lead
many, and specifically politicians charged with allocating
public funds, to withdraw their support for creating the
bank because of their moral objections to creating
embryos just to destroy them.
There are at least two things to say here. First, it could turn
out that public opposition to the use of embryos in this
way may not be as severe as might be anticipated. One
result of the lack of awareness of the problem of unequal
biological access among politicians, bioethicists, the
media and the general public is that there has not beenPhilosophy, Ethics, and Humanities in Medicine 2008, 3:22 http://www.peh-med.com/content/3/1/22
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much of a discussion of whether intentionally creating
embryos and harvesting hES cells from them can be justi-
fied as a way of addressing this problem. Thus, it remains
an open question whether most would continue to
oppose this use of embryos in face of the potential dispar-
ities the problem of unequal biological access identifies. It
is possible that many would be willing to support (albeit
reluctantly) this use of embryos to establish a stem cell
bank, if its use were limited to supplementing hES cell
lines derived from donated embryos.
Second, if morally uncontroversial methods for populat-
ing a stem cell bank fail to develop, and if it turns out that
we are still unwilling to create embryos with targeted gen-
otypes so that we can harvest hES cells from them, there
are other things that can be done that would at least miti-
gate the effects of the problem of unequal biological
access. For instance, it would help significantly if there
were a national registry of all the hES cell lines that are
publicly available, both those that qualify for federal
funding and those that do not, and one that provided the
information necessary for assessing the genetic diversity of
these lines. If agreement could be reached on how much
of the general population the hES cell lines available to
researchers need to cover to achieve just access to hES cell-
based therapies, such a registry would allow researchers to
identify where coverage is lacking and to use private or
state funds to create new hES cell lines to fill in the gaps.
Even without this agreement, a registry of this kind would
allow researchers to develop new lines from underrepre-
sented ethnic groups. The registry could also be combined
with any international registries that include the necessary
information for assessing the genetic diversity of the hES
cell lines they list, which would potentially increase cov-
erage of the general population.
How such a registry would be funded depends on how the
federal policy regulating hES cell research funding is
implemented by the NIH. Currently, the NIH requires
that research done with hES cell lines that do not qualify
for federal funding be kept completely separate from
research done with those lines that do qualify. This has led
to the creation of duplicate labs at some universities and
research institutions [35]. Given this interpretation of the
federal policy, it is unclear whether the use of federal
funds to create a national registry that includes those lines
that do not qualify for federal funding would be permitted
by the NIH. The fact that NIH Stem Cell Registry currently
lists only those hES cell lines that qualify for federal fund-
ing [4] suggests that it might not. If, in the end, the registry
cannot be created and maintained using federal funds, it
will need to be funded through state or private sources.
In any case, what is clear from the discussion in this paper
is that those of us in the United States must be responsive
to the concern that the problem of unequal biological
access may arise in our country. We cannot allow ethnic
disparities in access to hES cell-based therapies to occur.
This means that we need to be more aware of the problem
as hES cell research progresses towards providing these
therapies and to be more committed to ensuring that
access to them is fairly distributed among the general pop-
ulation. This leaves unanswered whether we have an obli-
gation to those in other countries to ensure their access to
hES cell based therapies. While important, addressing this
issue lies beyond the scope of this paper. But it is intrigu-
ing to consider whether the next step should be an inter-
national stem cell bank [36].
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